Synthesis and in vitro cytotoxic activities of sorafenib derivatives

A series of novel sorafenib derivatives have been designed and synthesized.The cytotoxic activities of these compounds were tested in three tumor cell lines.Most of the compounds showed potent antiproliferative activity against the tested cell lines with IC50= 0–20 mmol/L.Some compounds demonstrated...

Full description

Saved in:
Bibliographic Details
Published inChinese chemical letters Vol. 25; no. 5; pp. 702 - 704
Main Authors Wang, Ke, Li, Yan, Zhang, Li-Jing, Chen, Xiao-Guang, Feng, Zhi-Qiang
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.05.2014
Subjects
A549
ACHN
Antiproliferative activity
IC50
MDA-MB-231
Sorafenib
体外
化合物
合成
增殖活性
细胞毒活性
肿瘤细胞株
衍生物
Antiproliferative activity
Sorafenib
ACHN
MDA-MB-231
A549
Online AccessGet full text

Cover

More Information
Summary:A series of novel sorafenib derivatives have been designed and synthesized.The cytotoxic activities of these compounds were tested in three tumor cell lines.Most of the compounds showed potent antiproliferative activity against the tested cell lines with IC50= 0–20 mmol/L.Some compounds demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines.Among them,compound 5g demonstrated significant inhibitory activity against A549,ACHN and MDAMB-231 cell lines with IC50values of 1.29,1.99,3.11 mmol/L,respectively.
Bibliography:Sorafenib Antiproliferative activity A549 ACHN MDA-MB-231
11-2710/O6
A series of novel sorafenib derivatives have been designed and synthesized.The cytotoxic activities of these compounds were tested in three tumor cell lines.Most of the compounds showed potent antiproliferative activity against the tested cell lines with IC50= 0–20 mmol/L.Some compounds demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines.Among them,compound 5g demonstrated significant inhibitory activity against A549,ACHN and MDAMB-231 cell lines with IC50values of 1.29,1.99,3.11 mmol/L,respectively.
ISSN:1001-8417
1878-5964
DOI:10.1016/j.cclet.2014.03.020